Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V120.21.179.179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Emerging therapies for the treatment of essential thrombocythemia

  2018cites this paper
• Histone deacetylase inhibitors in myeloproliferative neoplasms: current roles and future prospects

  2016cites this paper
• How we diagnose and treat essential thrombocythaemia

  2015cites this paper
• Emerging drugs for the treatment of myelofibrosis

  2015cites this paper
• The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma

  2015cites this paper
• How We Treat Myeloproliferative Neoplasms.

  2015cites this paper
• Management of essential thrombocythemia, polycythemia vera, myelofibrosis: a practical approach and future directions

  2014cites this paper
• Therapy for myeloproliferative neoplasms: when, which agent, and how?

  2014cites this paper
• Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

  2014cites this paper
• Therapy for myeloproliferative neoplasms: when, which agent, and how?

  2014cites this paper
• Management of MPN beyond JAK2.

  2014cites this paper
• Update in the myeloproliferative neoplasms.

  2014cites this paper
• The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment

  2013cites this paper
• Novel therapies in the classical BCR–ABL-negative myeloproliferative neoplasms

  2013cites this paper
• Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary

  2013cites this paper
• Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

  2013cites this paper
• Pharmacological management of essential thrombocythemia

  2013cites this paper
• Molecular Classification of Myeloproliferative Neoplasms—Pros and Cons

  2013cites this paper
• Diagnosis and treatment of myelofibrosis: a personal perspective

  2013cites this paper
• JAK inhibitors: beyond spleen and symptoms?

  2013cites this paper